Depo-Provera Settlement Calculator 2026: Estimate Meningioma Claim Value
Use the Depo-Provera settlement calculator to organize potential claim factors after repeated Depo-Provera or depot medroxyprogesterone acetate injections and a later meningioma diagnosis, including injection history, treatment, neurological effects, medical records, wage loss and other damages.
- Organizes Depo-Provera injection history and diagnosis timing.
- Captures surgery, radiation, surveillance and neurological effects.
- Helps identify missing medical, pharmacy, wage and damages records.
- Separates official litigation/medical facts from editorial settlement estimates.
Get Your Depo-Provera Settlement Estimate
Answer the guided questions using your injection history, diagnosis, treatment, neurological symptoms, medical expenses and other documented losses.
Key Facts About Depo-Provera Meningioma Claims
Federal Depo-Provera products-liability cases are centralized in MDL No. 3140 before Judge M. Casey Rodgers in the Northern District of Florida. The JPML report dated August 3, 2026 lists 6,294 actions pending and 6,394 historical actions in the MDL.
Active Federal MDL
MDL 3140 coordinates common pretrial issues while individual plaintiffs retain individual claims and damages issues.
Official court page →6,294 Pending Actions
The August 3, 2026 JPML actions-pending report lists 6,294 actions in MDL 3140.
Official JPML reports →FDA Meningioma Warning
The current FDA-approved prescribing information states that meningioma cases have been reported following repeated administration, primarily with long-term use.
FDA prescribing information →Research Continues
Multiple observational studies have reported an association between injectable medroxyprogesterone acetate and meningioma risk, particularly with longer exposure.
Review study context →Who May Qualify for a Depo-Provera Lawsuit Review?
Eligibility is not determined by this page. Attorneys evaluating a potential claim may review the type and duration of medroxyprogesterone acetate injections, diagnosis timing, tumor type and location, treatment, medical proof, alternative risk factors, damages, defendants and applicable filing deadline.
Factors That May Support Review
- Documented Depo-Provera or depot medroxyprogesterone acetate injections before diagnosis
- Confirmed intracranial meningioma diagnosis supported by imaging or pathology
- Longer or repeated injection history documented in pharmacy, clinic or insurance records
- Surgery, radiation, neurological symptoms, surveillance or future-care needs
- Documented medical costs, wage loss, disability or quality-of-life impact
Issues Requiring Closer Review
- Unclear injection dates or product identity
- Diagnosis before use began
- Tumor type not clearly documented as an intracranial meningioma
- Missing imaging, pathology, pharmacy or provider records
- Statute-of-limitations, jurisdiction or other deadline concerns
Illustrative Depo-Provera Settlement Ranges
The ranges below are TortAdvisor editorial planning estimates based on injury severity, treatment burden, neurological impact, product-use proof and documented damages. They are not official averages, a court-approved matrix, settlement offers or guaranteed payouts.
Severe or Permanently Disabling Claim
$750,000–$1.5M+Complex surgery, radiation, recurrence, permanent neurological deficits, substantial future care, major wage loss or strong documented impairment.
TortAdvisor editorial estimate only. Actual result can be lower, higher or zero.Surgery or Moderate-Impact Claim
$300,000–$750,000Significant surgery or treatment, persistent symptoms, recovery limitations, lost income, ongoing monitoring and strong product-use records.
TortAdvisor editorial estimate only. Not an official settlement tier.Confirmed Diagnosis / Lower Treatment Burden
$100,000–$300,000Confirmed meningioma with surveillance or comparatively limited treatment, lower economic loss, fewer persistent symptoms or less complete documentation.
TortAdvisor editorial estimate only. Not a prediction of compensation.Depo-Provera, Medroxyprogesterone Acetate & Meningioma Research
The medical literature has developed quickly. The studies below are observational and should be read as population-level evidence rather than a diagnosis or individual causation determination.
BMJ 2024 National Case-Control Study
A French national case-control study reported an odds ratio of 5.55 for injectable medroxyprogesterone acetate and intracranial meningioma requiring surgery; the excess risk was driven by prolonged use of at least one year.
PubMed study record →U.S. Population Study
A U.S. retrospective cohort study reported a relative risk of 2.43 for meningioma diagnosis among depot medroxyprogesterone acetate users compared with controls, with higher-risk patterns tied to longer exposure.
PubMed study record →2026 Danish Population Study
A Danish case-control study reported an odds ratio of 4.55 for injectable medroxyprogesterone and incident meningioma, adding another population-level dataset to the evidence base.
PubMed study record →Evidence That Can Strengthen a Depo-Provera Claim Review
The calculator is most useful when answers can be tied to records rather than estimates from memory.
- Depo-Provera injection records and dates
- Pharmacy, OB-GYN, clinic or insurer records confirming use
- MRI or CT imaging confirming the meningioma
- Pathology, neurology, oncology or neurosurgery records
- Craniotomy, radiation and hospitalization records
- Records of seizures, vision loss, hearing changes, headaches or cognitive effects
- Medical bills and out-of-pocket expenses
- Lost-income and employment documentation
- Disability, caregiving and rehabilitation records
- Future-treatment or surveillance recommendations
- A dated injection-to-diagnosis timeline
- Documents showing the impact on normal activities and work
MDL No. 3140: Depo-Provera Litigation Status
MDL 3140 is pending in the Northern District of Florida before Judge M. Casey Rodgers. Multidistrict litigation coordinates common pretrial matters such as discovery and expert issues; it is not a class action and does not create a guaranteed settlement.
What Can Affect Depo-Provera Settlement Value?
1. Injection History
Duration, frequency, dose records and reliable proof of use can affect exposure analysis.
2. Tumor Characteristics
Location, size, recurrence, grade, symptoms and medical prognosis can affect treatment burden and damages.
3. Surgery & Treatment
Craniotomy, radiation, hospitalization, rehabilitation, surveillance and future care can materially affect losses.
4. Neurological Effects
Vision, hearing, seizure, balance, cognitive and other documented neurological limitations may affect damages.
5. Economic Loss
Medical expenses, wage loss, reduced earning capacity, disability and caregiving costs can increase documented damages.
6. Legal & Evidentiary Risk
Causation rulings, expert evidence, jurisdiction, deadlines, defendants and competing explanations can affect settlement posture.
How the Depo-Provera Settlement Calculator Works
The calculator organizes claim information into a preliminary educational model. It does not use one universal multiplier or substitute for medical, legal or records review.
1. Document Product Use
Enter injection duration and the strongest available records showing Depo-Provera or medroxyprogesterone acetate use before diagnosis.
2. Enter Diagnosis & Treatment
Use imaging, pathology, surgery, radiation, surveillance and neurological information whenever available.
3. Add Damages
Include medical expenses, wage loss, disability, future care, treatment burden and other documented losses.
Depo-Provera Lawsuit Filing Deadlines
There is no single national statute of limitations for every Depo-Provera claim. Deadlines can depend on state law, diagnosis date, discovery rules, prior proceedings, defendant-specific issues and other facts.
Related Depo-Provera & Settlement Resources
Depo-Provera Settlement Calculator FAQ
What does the Depo-Provera settlement calculator estimate?
It organizes product use, meningioma diagnosis, treatment, neurological effects and damages into an educational claim-value range. It does not predict an actual settlement.
What is the average Depo-Provera settlement amount?
No reliable universal average applies to an individual claim. Current projected ranges are editorial models, not a court-approved payout schedule.
How many Depo-Provera cases are currently pending in MDL 3140?
The JPML report dated August 3, 2026 lists 6,294 actions pending. The count can change as actions are filed, transferred, dismissed or otherwise resolved.
Does the FDA label mention meningioma?
Yes. The prescribing information revised in December 2025 includes a meningioma warning and says cases have been reported after repeated administration, primarily with long-term use.
Does research prove Depo-Provera caused my tumor?
No population study can make that individual determination by itself. Medical causation requires claim-specific medical and legal analysis.
Does using the calculator create an attorney-client relationship?
No. Using this website or calculator does not create an attorney-client relationship. Representation requires acceptance by a licensed attorney and an engagement agreement.
Request a Free Depo-Provera Case Review
If you were diagnosed with a meningioma after Depo-Provera use, use the calculator to organize your records or request a confidential screening.
Depo-Provera Litigation, FDA & Medical Sources
Northern District of Florida — MDL 3140
Official litigation page with current hearing dates, court documents and master-docket information.
Open official court page →JPML — August 3, 2026 Report
Official monthly report listing 6,294 actions pending in MDL 3140.
Open JPML pending-MDL reports →FDA — Depo-Provera CI Prescribing Information
Current federal labeling revised December 2025, including the meningioma warning and monitoring/discontinuation language.
Open FDA prescribing information →BMJ / PubMed — 2024 Study
French national case-control study evaluating selected progestogens and intracranial meningioma requiring surgery.
Open PubMed record →U.S. Medroxyprogesterone Study
U.S. population-based research examining depot medroxyprogesterone acetate and subsequent meningioma diagnosis.
Open PubMed record →2026 Danish Contraceptive Study
Population-level case-control research evaluating contraceptive progestogens and incident meningioma.
Open PubMed record →
